Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GE HealthCare Technologies (GEHC) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for GE HealthCare Technologies (GEHC) over the last 4 years, with Q4 2025 value amounting to $4.5 billion.

  • GE HealthCare Technologies' Cash & Equivalents rose 5606.64% to $4.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.5 billion, marking a year-over-year increase of 5606.64%. This contributed to the annual value of $4.5 billion for FY2025, which is 5606.64% up from last year.
  • GE HealthCare Technologies' Cash & Equivalents amounted to $4.5 billion in Q4 2025, which was up 5606.64% from $4.0 billion recorded in Q3 2025.
  • GE HealthCare Technologies' Cash & Equivalents' 5-year high stood at $4.5 billion during Q4 2025, with a 5-year trough of $504.0 million in Q3 2022.
  • Over the past 4 years, GE HealthCare Technologies' median Cash & Equivalents value was $2.4 billion (recorded in 2023), while the average stood at $2.4 billion.
  • As far as peak fluctuations go, GE HealthCare Technologies' Cash & Equivalents soared by 38015.87% in 2023, and later crashed by 346.98% in 2025.
  • GE HealthCare Technologies' Cash & Equivalents (Quarter) stood at $1.5 billion in 2022, then skyrocketed by 72.71% to $2.5 billion in 2023, then grew by 15.44% to $2.9 billion in 2024, then soared by 56.07% to $4.5 billion in 2025.
  • Its Cash & Equivalents was $4.5 billion in Q4 2025, compared to $4.0 billion in Q3 2025 and $3.8 billion in Q2 2025.